P
BTAI icon

&Partners’s BioXcel Therapeutics BTAI Stock Holding History

&Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
+80,864
New +$133K ﹤0.01% 2334

Other funds holding BTAI

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

&Partners's BTAI Position: Q1 2026 in Review

&Partners opened a new position in BioXcel Therapeutics (BTAI) in Q1 2026: 80,864 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #2334 among its holdings.

40 funds tracked by Wall St. Rank hold BTAI as of Q1 2026.

  • &Partners held 80,864 shares of BioXcel Therapeutics worth $108K as of Q1 2026.
  • BioXcel Therapeutics was a new &Partners position in Q1 2026.
  • BioXcel Therapeutics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2334 holding.
  • 40 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.